Cochrane Library Editorial - Contested effects and chaotic policies: the 2020 story of (hydroxy) chloroquine for treating COVID-19

During the past 12 months chloroquine and hydroxychloroquine have been touted as cures for COVID-19 and introduced into Covid-19 treatment protocols. This has led to increases in demand, leaving some rheumatoid arthritis and lupus patients deprived of effective treatments.A newly publishedCochrane Library Editorial explores the story of the assessment of  chloroquine and hydroxychloroquine efficacy and the lessons learnt. This Editorial publishes alongside the  recently published review published in the Cochrane Library   that concludes that hydroxychloroquine   has no clinical benefit in treating COVID-19 in hospitalised patients.View larger sized visual abstractRead the EditorialRead the Cochrane Review ' Chloroquine or hydroxychloroquine for prevention and treatment of COVID ‐19 'Read the Cochrane Clinical Answer ' For adults with coronavirus disease 2019 (COVID ‐19), what are the benefits and harms of hydroxychloroquine? 'Learn more about the visual abstracts created by Emory med studentsRead all the Cochrane resources and news on COVID-19Find out more about Cochrane COVID ReviewsThursday, March 25, 2021
Source: Cochrane News and Events - Category: Information Technology Authors: Source Type: news